Press Releases
Press Releases
-
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
-
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
-
Rezolute to Participate in Upcoming Investor Conferences in March
-
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
-
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
-
Rezolute Announces Change of Transfer Agent
-
FDA Clears Rezolute’s IND Application for RZ402
-
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Rezolute Announces Uplisting to the Nasdaq Capital Market
-
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
